Latest Regulation News

AXP Energy reports encouraging early oil and gas flowback at its Charlie #1 well in Oklahoma, marking a key milestone in its Mississippi Lime development program.

Infomedia Limited has secured Foreign Investment Review Board approval for its proposed acquisition by TPG Capital-backed McQueen BidCo, marking a key regulatory milestone. The Infomedia Board continues to recommend shareholder support ahead of upcoming votes.

Veganic SKN Ltd has launched legal action against Cancer Council Australia over alleged misleading claims about chemical UV filters in sunscreens, coinciding with recent product recalls and the company’s ambitious growth plans for 2026.

The Foreign Investment Review Board has extended its deadline for approving Mayne Pharma's acquisition by Cosette Pharmaceuticals, maintaining the current transaction timetable for now.

Tombador Iron Limited reports a quarterly loss amid a strategic acquisition of GoviEx Uranium, signaling a pivot to uranium exploration and a rebrand to Atomic Eagle Limited.

Hartshead Resources has been granted a two-year extension on Phase C of its UK North Sea Licence P2607, allowing more time to complete its work programme amid regulatory and supply chain delays.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, finding limited competition concerns amid evolving digital media landscapes.

The ACCC has decided not to oppose Southern Cross Media’s proposed acquisition of Seven West Media, citing limited competition concerns amid evolving digital media landscapes.

Ausgold Limited’s Katanning Gold Project has been fast-tracked through Western Australia’s new Priority Approvals Program, marking a key step toward a mid-2026 Final Investment Decision.

Sagalio Energy Limited has had its trading suspension lifted immediately following its response to an ASX Price Query, restoring market activity in its shares.

Sagalio Energy Limited’s shares have been suspended from ASX trading due to compliance concerns, leaving investors in the dark about the company’s next steps.

Actinogen Medical’s XanaMIA Phase 2b/3 trial for Alzheimer’s disease has received a positive safety recommendation from its independent Data Monitoring Committee, allowing the study to proceed unchanged. Investors now await the critical efficacy analysis scheduled for January 2026.